120 related articles for article (PubMed ID: 21178268)
21. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
[TBL] [Abstract][Full Text] [Related]
22. [Correlation between TCF7L2 gene polymorphism and genetic susceptibility in women with gestational diabetes mellitus].
Shi X; Cai Q; Zou M; Shen Y
Zhonghua Fu Chan Ke Za Zhi; 2014 Aug; 49(8):588-93. PubMed ID: 25354859
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of fatty acid synthase in prostate cancer recurrence: SUV of [(11) C]acetate PET as a prognostic marker.
Leisser A; Pruscha K; Ubl P; Wadsak W; Mayerhöfer M; Mitterhauser M; Hacker M; Kramer G; Shariat S; Karanikas G; Hartenbach M; Haug AR
Prostate; 2015 Nov; 75(15):1760-7. PubMed ID: 26282590
[TBL] [Abstract][Full Text] [Related]
24. Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer.
Fukuda H; Tsuchiya N; Narita S; Kumazawa T; Horikawa Y; Inoue T; Saito M; Yuasa T; Matsuura S; Satoh S; Ogawa O; Habuchi T
Oncol Rep; 2007 Nov; 18(5):1155-63. PubMed ID: 17914566
[TBL] [Abstract][Full Text] [Related]
25. Overall and relapse-free survival in oropharyngeal and hypopharyngeal squamous cell carcinoma are associated with genotypes of T393C polymorphism of the GNAS1 gene.
Lehnerdt GF; Franz P; Zaqoul A; Schmitz KJ; Grehl S; Lang S; Schmid KW; Siffert W; Jahnke K; Frey UH
Clin Cancer Res; 2008 Mar; 14(6):1753-8. PubMed ID: 18347176
[TBL] [Abstract][Full Text] [Related]
26. Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy.
Koie T; Ohyama C; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Hosogoe S; Yamamoto H; Kitayama M; Hirota K
Int J Clin Oncol; 2016 Apr; 21(2):379-383. PubMed ID: 26223693
[TBL] [Abstract][Full Text] [Related]
27. KLK2 single-nucleotide polymorphism rs198977 is associated with increased susceptibility and hyperleukocytosis in AML.
Meng G; Li P; Li M; Wu Y; Ma Y; Sun T; Ji C
Front Genet; 2023; 14():1218523. PubMed ID: 37593117
[No Abstract] [Full Text] [Related]
28. hTERT gene polymorphism correlates with the risk and the prognosis of thyroid cancer.
Gong L; Xu Y; Hu YQ; Ding QJ; Yi CH; Huang W; Zhou M
Cancer Biomark; 2016 Jul; 17(2):195-204. PubMed ID: 27472887
[TBL] [Abstract][Full Text] [Related]
29. Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer.
Burdick MJ; Reddy CA; Ulchaker J; Angermeier K; Altman A; Chehade N; Mahadevan A; Kupelian PA; Klein EA; Ciezki JP
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1439-45. PubMed ID: 18963536
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Value of Prostaglandin-endoperoxide Synthase 2 Polymorphisms in Prostate Cancer Recurrence after Radical Prostatectomy.
Lee CH; Pao JB; Lu TL; Lee HZ; Lee YC; Liu CC; Huang CY; Lin VC; Yu CC; Yin HL; Huang SP; Bao BY
Int J Med Sci; 2016; 13(9):696-700. PubMed ID: 27647999
[TBL] [Abstract][Full Text] [Related]
31. Presence of high grade tertiary Gleason pattern upgrades the Gleason sum score and is inversely associated with biochemical recurrence-free survival.
Turker P; Bas E; Bozkurt S; Günlüsoy B; Sezgin A; Postacı H; Turkeri L
Urol Oncol; 2013 Jan; 31(1):93-8. PubMed ID: 21316989
[TBL] [Abstract][Full Text] [Related]
32. The novel tumor-suppressor Mel-18 in prostate cancer: its functional polymorphism, expression and clinical significance.
Wang W; Yuasa T; Tsuchiya N; Ma Z; Maita S; Narita S; Kumazawa T; Inoue T; Tsuruta H; Horikawa Y; Saito M; Hu W; Ogawa O; Habuchi T
Int J Cancer; 2009 Dec; 125(12):2836-43. PubMed ID: 19585577
[TBL] [Abstract][Full Text] [Related]
33. PSCA rs1045531 Polymorphism and the Risk of Prostate Cancer in a Chinese Population Undergoing Prostate Biopsy.
Zhang X; Hu Q; Chen Y; Li M; Yin H; Zhou C; Li G; Hou J
Technol Cancer Res Treat; 2017 Dec; 16(6):1168-1172. PubMed ID: 29332451
[TBL] [Abstract][Full Text] [Related]
34. Genetic predisposition to early recurrence in clinically localized prostate cancer.
Borque Á; del Amo J; Esteban LM; Ars E; Hernández C; Planas J; Arruza A; Llarena R; Palou J; Herranz F; Raventós CX; Tejedor D; Artieda M; Simon L; Martínez A; Carceller E; Suárez M; Allué M; Sanz G; Morote J
BJU Int; 2013 Apr; 111(4):549-58. PubMed ID: 22759231
[TBL] [Abstract][Full Text] [Related]
35. Maintenance of low inflammation level by the ZFHX3 SNP rs2106261 minor allele contributes to reduced atrial fibrillation recurrence after pulmonary vein isolation.
Tomomori S; Nakano Y; Ochi H; Onohara Y; Sairaku A; Tokuyama T; Motoda C; Matsumura H; Amioka M; Hironobe N; Ookubo Y; Okamura S; Kawazoe H; Chayama K; Kihara Y
PLoS One; 2018; 13(9):e0203281. PubMed ID: 30180182
[TBL] [Abstract][Full Text] [Related]
36. The role of p21 3'UTR gene polymorphism in the risk of prostate cancer: a pilot study.
Sivoňová MK; Vilčková M; Jurečeková J; Hatok J; Dobrota D; Dušenka R; Kliment J
Mol Med Rep; 2013 Mar; 7(3):986-90. PubMed ID: 23292332
[TBL] [Abstract][Full Text] [Related]
37. Predicting the 5-Year Risk of Biochemical Relapse After Postprostatectomy Radiation Therapy in ≥PT2, pN0 Patients With a Comprehensive Tumor Control Probability Model.
Fiorino C; Broggi S; Fossati N; Cozzarini C; Goldner G; Wiegel T; Hinkelbein W; Karnes RJ; Boorjian SA; Haustermans K; Joniau S; Palorini F; Shariat S; Montorsi F; Van Poppel H; Di Muzio N; Calandrino R; Briganti A
Int J Radiat Oncol Biol Phys; 2016 Oct; 96(2):333-340. PubMed ID: 27497691
[TBL] [Abstract][Full Text] [Related]
38. C-reactive protein haplotype is associated with high PSA as a marker of metastatic prostate cancer but not with overall cancer risk.
Eklund CM; Tammela TL; Schleutker J; Hurme M
Br J Cancer; 2009 Jun; 100(12):1846-51. PubMed ID: 19436291
[TBL] [Abstract][Full Text] [Related]
39. Outcomes and prognostic factors in intermediate-risk prostate cancer: multi-institutional analysis of the Spanish RECAP database.
Hervás A; Pastor J; González C; Jové J; Gómez A; Casaña M; Villafranca E; Mengual JL; Muñoz V; Henriquez I; Muñoz J; Collado E; Clemente J
Clin Transl Oncol; 2019 Jul; 21(7):900-909. PubMed ID: 30536208
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients.
Kurek R; Nunez G; Tselis N; Konrad L; Martin T; Roeddiger S; Aumüller G; Zamboglou N; Lin DW; Tunn UW; Renneberg H
Clin Cancer Res; 2004 Sep; 10(17):5808-14. PubMed ID: 15355910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
